<DOC>
	<DOCNO>NCT00953732</DOCNO>
	<brief_summary>This study design follow patient achieve complete clearance AK lesion Day 57 visit complete PEP005-016 PEP005-025 study 12 month period ass recurrence Actinic Keratosis ( AK ) lesion long term safety select treatment area .</brief_summary>
	<brief_title>A Long Term Follow Study Patients Who Have Completed PEP005-016 PEP005-025 Studies</brief_title>
	<detailed_description>A 12 month long-term follow-up study patient achieve complete clearance AK lesion Day 57 Phase 3 study PEP005-016 PEP005-025 .</detailed_description>
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<criteria>Patient must achieve complete clearance AK lesion ( lesion count = 0 ) Day 57 one follow Peplin AK clinical study : PEP005016 PEP005025 Patient provide informed consent document signing Informed Consent Form ( ICF ) prior studyrelated procedure Concurrent participation another research study would involve select treatment area ( except poststudy followup visit previous Peplin AK study ) Early termination study PEP005016 PEP005025</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Peplin</keyword>
	<keyword>Actinic keratosis</keyword>
	<keyword>PEP005</keyword>
</DOC>